Posts

Showing posts from October, 2016

Diwali to Diwali Best Performers

Last Diwali to This Diwali  : 100 %  & above = 122 stocks                                                      50%  & above = 339 stocks STOCK in  %                                   % STOCK in Alphapet               % DONEAR 492.74% A2ZINFRA 81.80% ENERGYDEV 474.38% ACCELYA 50.97% LAKSHMIEFL 468.02% ADFFOODS 99.03% UPERGANGES 452.68% ADI 135.27% CINELINE 430.49% AEGISCHEM 70.25% STOREONE 403.32% AGARIND 115.48% TIRUMALCHM 368.91% AKSHOPTFBR 54.83% DYNATECH 364.18% ALANKIT 187.22% ELECTHERM 354.39% ALKALI 92.37% JAYAGROGN 353.46% ALLSEC 202.14% MANAPPURAM 352.99% ALMONDZ 70.19% STARPAPER 341.50% ALPHAGEO 91.54% TATAMETALI 324.29% AMDIND 60.81% SUMEETINDS 321.08% ANANTRAJ 59.57% UGARSUGAR 299.
Image

Small Idea. Big Wealth...

Image

Energizing Wealth...

Image
Image

Thirumalai Chemicals - SHARPEST & SHORTEST

Image
TIRUMALCHM -   Identified only in June that too after it doubled from the March  Low. Now, it tripled,  even from the identified level  within 4 Months, Still, move not yet over. Sharp move at the shortest period.  ***

NIFTY - mode/mood

Image
In the last two months, movement indicates the mode/mood. why so obvious ?  

Person - Persona - Personality

Image
E-MUSEUM  of SLK (really a beautiful presentation)

Expect XXXX % absolute Return in XX Months.

Image

Made to Measure

Image
Entering the high road,  Expecting the long journey.  *** FIVE YEAR HISTORY

POTENTIAL TO GROW 130 %

Image
eVen more, from the current lVeles
Image

"He has an insatiable hunger to grow bigger and bigger,"

Image
Dilip Shanghvi  -     India’s second-biggest   after  Dhirajlal Hirachand   Dhirubhai   Ambani   When Dilip Shanghvi wants something, he has a track record of getting it.  One executive, Srinivas Lanka, recalls the founder of Sun Pharmaceuticals Industries Ltd. calling more than 100 times over three years with a job offer two decades ago. Shanghvi was setting off on an acquisition-fueled strategy to transform his small generic drugmaker into an industry powerhouse, and he wouldn’t take no for an answer. In the end, Shanghvi won over Lanka, who agreed to leave his job at global pharma giant Novartis AG and sign on as the executive director in charge of Sun’s Indian business in 1996, staying until 1999. "A lot of entrepreneurs used to call me, but not many had this kind of fire in their belly," said Lanka. "I thought this guy has some different blood in him." That kind of relentless drive has helped make Sun India’s biggest drugmaker and bes